Business Context and Reporting Period
Company: Repligen Corporation (Repligen)
Filing Type: Form 10-K (Annual Report)
Period Ended: March 31, 2007
Business Overview: Repligen is a biopharmaceutical company developing novel therapeutics for central nervous system diseases. Its current revenue is derived from two commercial products: Protein A (used in monoclonal antibody purification) and SecreFlo (a diagnostic aid for pancreatic disorders). The company funds its therapeutic development programs using profits from these commercial products.
Key Financial Metrics
| Metric | Fiscal 2007 | Fiscal 2006 | Fiscal 2005 |
|---|---|---|---|
| Total Revenue | $14,074,000 | $12,911,000 | $9,360,000 |
| Product Revenue | $13,074,000 | $12,529,000 | $9,360,000 |
| Net Income (Loss) | $(889,000) | $697,000 | $(2,984,000) |
| Operating Loss | $(1,825,000) | $(1,220,000) | $(4,162,000) |
| Research & Development | $5,924,000 | $5,163,000 | $5,037,000 |
| Cash & Marketable Securities | $22,627,000 | $23,408,000 | $23,523,000 |
| Working Capital | $22,394,000 | $18,575,000 | $15,673,000 |
| Long-term Obligations | $200,000 | $231,000 | $120,000 |
Note: Fiscal 2006 included a one-time "Other Income" of $1,170,000 from a settlement with ChiRhoClin, which significantly impacted net income for that year.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 9% to $14.1 million, driven by a 6% increase in Protein A sales ($11.1 million) despite a 13% decrease in volume, offset by favorable product mix pricing. SecreFlo sales declined 2% to $1.9 million due to competition from its sole supplier and reduced marketing efforts.
- Profitability: The company reported a net loss of $889,000 in 2007, compared to a net profit of $697,000 in 2006. The 2006 profit was largely due to the non-recurring $1.17 million settlement gain. Excluding this, operating performance remained consistent with historical trends of operating losses.
- Expense Increases: Operating expenses rose 13% to $15.9 million. Selling, General, and Administrative (SG&A) expenses increased 17%, primarily due to the adoption of SFAS No. 123(R) requiring stock-based compensation expense recognition ($582,000) and increased personnel costs. R&D expenses increased 15% due to higher clinical trial costs for Uridine and Secretin programs.
- Liquidity: Cash and marketable securities decreased slightly by $781,000 to $22.6 million. Operating cash flow was positive at $405,000.
Guidance, Outlook, and Risks
- Outlook: Management expects R&D and SG&A expenses to increase in fiscal 2008 due to ongoing clinical trials and litigation costs. Protein A sales are expected to grow but remain subject to quarterly fluctuations. SecreFlo revenues are expected to decline by one-third in fiscal 2008 as the company reduces marketing efforts; product supply is expected to cease in fiscal 2009.
- Clinical Progress:
- Secretin for MRI: Phase 2 trial results announced in May 2007 showed a ~20% improvement in sensitivity for detecting pancreatic duct abnormalities.
- Uridine for Bipolar Depression: Phase 2 trial enrollment completed; top-line data expected later in 2007.
- Friedreich's Ataxia: Entered an exclusive license agreement with The Scripps Research Institute in April 2007 for compounds that increase frataxin protein production.
- Legal Proceedings:
- ImClone Systems: Repligen and MIT won a summary judgment in July 2006 regarding patent infringement for Erbitux production. Trial is pending for damages.
- Bristol-Myers Squibb: Lawsuit filed regarding patent infringement for Orencia (CTLA4-Ig). Jury selection scheduled for April 2008.
- Risks: Dependence on a single supplier (ChiRhoClin) for SecreFlo; reliance on third-party manufacturers; uncertainty of clinical trial outcomes; and the need for additional capital to fund development if commercial revenues do not suffice.
Investor Verification Checklist
- Supplier Dependency: Verify the status of the supply agreement with ChiRhoClin for SecreFlo and the timeline for supply cessation in 2009.
- Legal Outcomes: Monitor the status of the ImClone and Bristol-Myers Squibb patent infringement lawsuits, as potential damages could be material.
- Clinical Data: Await the release of top-line data for the Uridine Phase 2 trial (expected late 2007) and FDA discussions regarding Secretin for MRI.
- Cash Runway: Confirm that current cash balances ($22.6 million) are sufficient to fund operations for the next 24 months as stated by management, given the expected increase in R&D and legal expenses.
- Customer Concentration: Note that 72% of foreign revenue (and a significant portion of total revenue) is attributable to two customers (GE Healthcare and Applied Biosystems).